Journal
DRUG DISCOVERY TODAY
Volume 20, Issue 4, Pages 422-434Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2014.11.004
Keywords
-
Categories
Funding
- Education Office of the Novartis Institutes for Biomedical Research
Ask authors/readers for more resources
Vast amounts of bioactivity data have been generated for small molecules across public and corporate domains. Biological signatures, either derived from systematic profiling efforts or from existing historical assay data, have been successfully employed for small molecule mechanism-of-action elucidation, drug repositioning, hit expansion and screening subset design. This article reviews different types of biological descriptors and applications, and we demonstrate how biological data can outlive the original purpose or project for which it was generated. By comparing 150 HI'S campaigns run at Novartis over the past decade on the basis of their active and inactive chemical matter, we highlight the opportunities and challenges associated with cross-project learning in drug discovery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available